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Abstract 
A series of bimodal metabotropic glutamate-receptor targeted MRI contrast agents has been 
developed and evaluated, based on established competitive metabotropic Glu receptor subtype 
5 (mGluR5) antagonists. In order to directly visualise mGluR5 binding of these agents on the 
surface of live astrocytes, variations in the core structure were made. A set of gadolinium 
conjugates containing either a cyanine dye or a fluorescein moiety was accordingly prepared, 
to allow visualisation by optical microscopy in cellulo. In each case, surface receptor binding 
was compromised and cell internalisation observed. Another approach, examining the 
location of a terbium analog via sensitised emission also exhibited non-specific cell uptake in 
neuronal cell line models. Finally, biotin derivatives of two lead compounds were prepared, 
and the specificity of binding to the mGluR5 cell surface receptors was demonstrated with the 
aid of their fluorescently labelled avidin conjugates, using both total internal reflection 
fluorescence (TIRF) and confocal microscopy. 
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Introduction 
The human brain is a complex system in both intuitive and computational terms. It is 
involved in the processing of cognitive, sensory and motor information via neurons which are 
one of the basic building blocks of the nervous system.
(1, 2)
 Chemical neurotransmitters are 
involved in signal transmission through neurons. One of the active chemical messengers, 
Glutamate (Glu) is abundantly distributed in the mammalian central nervous system (CNS), 
and plays a critical role in mediating excitatory signals through both G-protein-coupled 
metabotropic receptors and ligand-gated ionotropic receptors present on the post-synaptic 
neuronal cells.
(1-3)
 The metabotropic Glu receptor subtype 5 (mGluR5) is known to be actively 
involved in modulating excitatory signals via a heterogeneous family of G-protein-coupled 
receptors that are activated by Glu.
(4, 5)
 An imbalance of Glu concentration and loss of their 
corresponding receiving mGluR5 in the synaptic cleft have been implicated in a number of 
CNS disorders, such as pain, anxiety, depression, Parkinson’s disease, and addiction.(1, 4, 6, 7) 
The non-invasive imaging of the brain using a powerful technique like Magnetic Resonance 
Imaging (MRI) [high spatial resolution imaging (≤ 200 µm)] has revolutionised our 
understanding of the brain’s organisational and operational complexity.(8) MR imaging 
procedures can be substantially improved when applied in combination with paramagnetic 
contrast agents (CAs) to enhance sensitivity and image quality. Gadolinium (Gd
3+
)-based CAs 
are used because of their high spin paramagnetism and the slow electronic relaxation of Gd
3+
, 
which influence the longitudinal and transverse relaxation times (T1, and T2,) of surrounding 
water protons, thereby altering the image contrast during MR measurements [9]. The use of 
non-specific CAs show enhanced sensitivity and image quality, thereby improving the 
accuracy of prognoses in clinical applications. The sensitivity and specificity of imaging can 
be augmented several fold by introduction of “Responsive CAs (RACs)”. These agents 
respond to changes in their surroundings by sensing changes in the biochemical environment, 
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following spatially localized neural activation. In principle, these RCAs may exhibit relaxivity 
change by modulation of three parameters: (i) the number of water molecules bound directly 
to the gadolinium ion (q); (ii) the water exchange rate (kex); and (iii) the molecular rotational 
correlation time (τR). These changes can be detected and quantified by MRI [9]. We and 
others have published reports of pH, enzyme and Ca
2+
 sensitive RCAs, for example [10, 11].  
A key challenge in neuroimaging is to develop appropriate ‘chemical tools’ for MRI to 
detect synaptic glutamate fluctuations non-invasively. One approach could be to target Glu 
directly, by making small chemical entities. The design of such chemical entities is hampered 
by low selectivity towards Glu in comparison to similar amino acids such as aspartate or 
glutamine. In our approach, we follow an indirect path and target mGluR5 located on the 
postsynaptic membranes that are modulated by glutamate upon neuronal firing. In order to 
devise a probe that functionally reports the Glu fluctuation, it is important that even during 
signal transduction the probe should mainly remain on the membrane surface bound to the 
receptors and not be internalised by receptor-mediated endocytosis.  
Recently, we introduced a new set of chemical tools based on an antagonistic approach to 
target mGluR5 and detect changes in glutamate concentration.
(9)
 The results from a functional 
cellular calcium assay (potent antagonistic effects; 3.9±0.9 and 3.1±0.3, respectively) and the 
enhancement of receptor mediated cellular relaxation rates (R1,cell = 32% and 28%, 
respectively) at 3T revealed that two MRI probes ([Gd.L
3 and 8
]) (Figure 1) specifically 
interacted with cellular mGluR5.
(10)
 However, the observed increase in R1,cell could also result 
from internalisation of the complex, via receptor-mediated endocytosis. Probe-receptor 
interaction assays at low temperature using MRI suggested that the probe interacted with cell 
surface receptors but may also have been taken up into cells.
(10)
 Nonetheless, there is no direct 
proof to confirm that the compound is indeed specifically interacting with mGluR5 on the live 
cell surface and is not getting internalised in cells through receptor-mediated endocytosis. 
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Furthermore, due to the intrinsic insensitivity of MR imaging compared to optical imaging, it 
is impossible to visualise the complexes [Gd.L
3 and 8
] directly in/on cells. Hence, a series of 
bifunctional imaging probes was designed to allow real-time visualisation of the live cell 
surface receptors, using high-resolution fluorescence microscopic methods (Figure 1). 
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Figure 1. Structures of the imaging probes examined in this study. 
Results and Discussion 
Synthesis of bifunctional imaging probes 
In order to allow the direct visualisation of the cell surface mGluR5, we designed 
characterised and evaluated three sets of imaging probes (fluorescently labelled [L
1,2,6 and 7
] 
and MRI probes [Gd.L
4-5 and 9-10
] (Figure 1). These probes were synthesised using alkyne and 
dipyridyl amide derived antagonistic amines [A and B]. These amine precursors were 
synthesised using a range of standard synthetic transformations including Suzuki/ 
Sonogashira coupling, alkylation, amide formation, protection and de-protection (ESI
†
: 
Scheme S1).  
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Scheme 1. Reagents, conditions, and yields: a) DIPEA, DMF, RT, 18-22%; b) H2O, pH=8, 
RT, 32-41%. 
The four fluorescent probes [L
1,2,6 and 7
] were synthesised using either cyanine 5.5 NHS 
ester with Hünig’s base in DMF or fluorescein isothiocyanate at pH 8-8.5 in water, in single 
step conjugation reactions with the antagonistic amines, A and B (Scheme 1). In FITC 
conjugation, the pH was not allowed to exceed 8.5 because at pH >9, lactone cleavage of the 
FITC part occurs, leading to the formation of a side product. 
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Scheme 2. Reagents, conditions, and yields: a) Na2CO3, MeCN, 60°C, 40%; b) K2CO3, 
MeCN, 80°C, 30-40%; c) NaOH, H2O:MeOH (1:9), RT; d) A/B, HOBt, NMM, EDC, DMF, 
RT, 20-28%; e) 11/12/17/18, CH2Cl2:TFA (1:9), RT; f) L
4
/L
9
/17/18, LnCl3.6H2O 
(Ln
3+
=Gd
3+
/Tb
3+
), H2O, pH 5.5, 80°C; g) (i) 15, 0.15 M Ba(OH)2, glyme, H2O, 80°C (ii) 
CH2Cl2:TFA (1:9), RT, 78%; h)  (i) 16, 10% PdC, MeOH, 40 psi, RT (ii ) CH2Cl2:TFA (1:9), 
RT, , 65%; i) D-Biotin, HATU, DIPEA, DMF, RT, 15-22%. 
The azaxanthone based antagonistic lanthanide complexes, [Ln.L
4 and 9
] were synthesized 
as depicted in Scheme 2. Alkylation of the tert-butyl ester of 1,7-bis(carboxymethyl)-
1,4,7,10-tetraazacyclododecane (DO2A) by the (S)-5-benzyl 1-tert-butyl 2-
bromopentanedioate (C)
(11)
 yielded the protected DO2A-GA (8). Subsequent treatment of 8 
with 2-bromo-N-((5-oxo-5H-chromeno[2,3-b]pyridin-2-yl)methyl)acetamide (E) and Hünig’s 
base in anhydrous MeCN yielded tetra substituted intermediate 9, from which the carboxylic 
acid 10 was obtained following basic hydrolysis of the benzyl group. The azaxanthone 
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bromoamide (E) was synthesized via alkylation of 2-(aminomethyl)-5-H-chromeno[2,3-
b]pyridin-5-one
(11)
 (as previously reported) with 2-bromoacetyl bromide in MeCN. The acid, 
10, was coupled with the amines A and B, using N’-(3-dimethylaminopropyl)-N-
ethylcarbodiimide (EDC), 1-hydroxybenzotriazole (HOBt) and N-methylmorpholine (NMM) 
in DMF, to afford the protected amides, 11 and 12 respectively. Following removal of the 
ester groups with TFA, the desired lanthanide complexes, [Ln.L
4 and 9
], were formed by 
treatment with LnCl3·6H2O (Gd
3+ 
and Tb
3+
) at pH 6.5.  
The biotin coupled antagonistic gadolinium complexes, [Gd.L
5 and 10
], were synthesized in 
7 steps as shown in Scheme 2. Alkylation of 8 with (S)-tert-butyl 6-
(benzyloxycarbonylamino)-2-bromohexanoate (D)
(12)
 gave the compound 13, which was 
further treated with base, cleaving the benzyl group to afford the acid 14. The tetra-esters 15 
and 16 were synthesized by coupling the amines A/B and acid 14 by using standard 
carbodiimide methodology [EDC/HOBt/NMM]. The intermediate amines, 17 and 18, were 
obtained by successive deprotections (benzylcarbamate removal by 0.15 M Ba(OH)2, glyme 
for alkyne amine; hydrogenation using PdC as the catalyst for dipyridyl amine and tert-butyl 
groups with CH2Cl2:TFA). Ligands, 17 and 18 were loaded with Gd
3+
 using GdCl3·6H2O in 
water at pH 6.5. The amines of Gd.17 and Gd.18 were coupled to the carboxylic acid group 
of D-biotin, using HATU and DIPEA in DMF, to afford the final complexes, [Gd.L
5 and 10
] 
respectively.  
The final complexes [Ln.L
4 and 9
] and [Gd.L
5 and 10
], were purified by reverse phase HPLC 
and the metal ion concentration of [Tb.L
4 and 9
] and [Gd.L
4-5 and 9-10
] was measured using 
Evans' bulk magnetic susceptibility measurements.
(13)
 The longitudinal proton relaxivities 
(r1p) of [Gd.L
4-5 and 9-10
] were measured in aqueous solution (pH 7.4) at 37°C and 1.4 T, and 
found to be 7.49, 7.23, 7.98 and 7.88 mM
-1
 s
-1
, respectively. Such values are slightly higher 
than those reported for related mono-aqua gadolinium complexes, 
(14)
 as a consequence of 
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their bigger molecular volume and slower rotational correlation time, coupled to a fast water 
exchange rate  and a significant second sphere contribution to the overall relaxivity. The 
relative importance of this effect has been emphasised earlier. 
(15, 16)
  
Biochemical evaluation of imaging probes 
Cellular receptor expression and cytotoxicity 
The in vitro receptor binding behaviour of the newly modified imaging probes was 
investigated on cortical rat astrocytes that are known to express functional mGluR5 
abundantly.
(17)
 Optical microscopy studies were undertaken with cultured mGluR5 expressing 
secondary astrocytes (ESI
†
). The secondary astrocytes were obtained from frozen- harvested, 
confluent primary astrocytes cultures which were gently thawed, and re-cultured on surface-
modified glass chamber slides (ESI). The medium was changed after 24h to allow the cells to 
attach to the chamber slide surface. Fresh G-5 supplement (Invitrogen) containing medium 
was used to increase the expression of mGluR5 
(18)
 and the cells were used for the microscopy 
studies after 4 days. The expression of mGluR5 was confirmed by immunofluorescence 
staining methods (Figure S1
†
). 
(9, 10)
 In vitro MRI studies were done on primary astrocytes as 
explained earlier.
(9, 10)
 None of the imaging probes (up to 200 µM) induced any significant 
cytotoxicity on astrocytes after 24 h of incubation, as observed in a metabolic activity test for 
mitochondrial dehydrogenase activity (XTT assay) (data not shown).  
Microscopic techniques used to visualise mGluR5 on live astrocytes 
To investigate the cellular distribution of these imaging probes, two fluorescence imaging 
techniques have been used. Total internal reflection fluorescence (TIRF) microscopy was 
used to analyse the localisation of the probes near the plasma membrane. Due to its 
experimental design, TIRF microscopy facilitates very shallow depth penetration and 
primarily illuminates the fluorophores near to the cover slip adhered cell surface; hence the 
signal from intracellular regions is reduced to a minimum.
(19)
 A signal from the imaging 
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probes at a maximum distance of 150 nm from the plasma membrane could be obtained 
employing this microscopy technique. Using the same cell preparations, live-cell laser 
scanning confocal microscopy (LSCM) studies were also performed. Extracellular receptor 
tagging and/or intracellular localisation of probes in the entire cell was observed. Depth 
profiling ‘z-stacks’ were recorded, selectively scanning through well-defined sub-cellular 
sections of the cell. These z-stacks were subjected to 3D-reconstruction, in order to clearly 
depict the distribution of the imaging probes in/on the astrocytes. 
Fluorescently labelled probes 
In the first attempt to visualise mGluR5 on live astrocytes, the first set of four optical probes 
[L
1 and 6
] (1 µM) and [L
2 and 7
] (10 µM) were incubated on cultured astrocytes for 15 or 45 min 
(37°C, 5% CO2). After incubation, the cells were washed twice with Hank's balanced salt 
solution (HBSS) to remove unbound material. The Cy5.5 conjugated probes, [L
1 and 6
] (Figure 
1), showed a complete intracellular distribution in mGluR5 expressing astrocytes. No signal 
was obtained in TIRF microscopy but a punctate intracellular distribution was observed in 
epifluorescence mode (data not shown). The mitochondrial distribution of [L
1 and 6
] was 
confirmed using the commercial stain, MitoTracker (Invitrogen) (500 nM) and co-incubation 
with [L
1 and 6
] (1 µM) (Figure S2). Such observations indicate that in this case the cellular 
distribution of the probes is not driven by the receptor binding moiety but instead is 
determined by the larger Cy5.5 fluorophore subunit. The structural and charge similarity of 
Cy5.5 to the mitochondrial dye may partly explain the intracellular distribution of the probes.  
On the other hand, the fluorescein conjugated probes (Figure 1), [L
2 and 7
] (10 µM, 45 min) 
could be visualised on the cell surface of astrocytes using TIRF microscopy. However, by 
examining the epifluorescence images recorded by TIRF and the intracellular planes obtained 
from LSCM, it was confirmed that these probes were also present in intracellular regions 
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(Figure S3
†
). The conjugate L
7
 was brighter both on the cell surface and inside, consistent 
with better receptor binding/uptake of this probe compared to L
2
. In the past, we
(20-23)
 and 
others 
(24, 25)
 have shown that a consequence of appending a membrane permeable (relatively 
lipophilic) fluorescent moiety can be to perturb cell-uptake mechanisms, thereby promoting 
non-specific cell internalisation of the probe. Therefore, these fluorescently labeled probes 
[L
1,2,6 and 7
] were not considered to be appropriate to visualise cell-surface mGluR5 and 
therefore should not be compared with the MR performance of the parent probes [Gd.L
3 and 8
], 
that gave rise to the observed receptor mediated R1,cell enhancements.  
Luminescent probes based on terbium emission 
In an alternative approach, azaxanthone-based luminescent probes, [Tb.L
4 and 9
] (Figure 1) 
were designed to tag and visualise mGluR5. In this set of imaging probes, we preserved the 
parent molecular structures [Gd.L
3 and 8
] and appended the luminophore on the trans-position 
of [Gd.L
3 and 8
] (i.e. about 10Å away) to allow visualization by optical microscopy. 
Terbium(III)  complexes of [L
4 and 9
] were incubated with cultured secondary astrocytes for 
either 10 or 45 min, using 10 or 100 µM loading concentrations, at 37°C, 5% CO2 and cells 
were washed twice with HBSS to remove any unbound probe that may be present. In order to 
present high quality microscopy images with adequate brightness and S/N ratio, e.g. to 
compensate for lower probe emission/uptake, a 100 µM loading concentration at 45 min was 
finally used. The cellular localisation profile of the complexes was observed by examining the 
terbium emission (450 – 570 nm) by fluorescence microscopy, following excitation of the 
azaxanthone chromophore at 355 nm. Optical sections through the cell were examined by 
LCSM, and confirmed that these two complexes were also distributed within the cell, 
consistent either with cell surface receptor mediated or non-specific uptake (Figure S4
†
).  
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In the past, we have identified that such amide-linked azaxanthone sensitising moieties 
promote probe uptake into the cell by macropinocytosis.
(26)
 We have also observed that small 
structural modifications to the chromophore of a family of emissive Tb
3+
 complexes have an 
influence on the cellular compartmentalization profile.
(23, 27)
 Therefore, by virtue of the 
lipophilic nature of the azaxanthone moiety, the distribution of these molecules may also not 
be directly compared to the behaviour of the parent complexes, [Gd.L
3 and 8
].  
Microscopic visualisation by complex conjugate interactions based on biotin/avidin 
In order to target and visualise mGluR5 on the cell surface selectively, we needed to perturb 
the parent MRI probe [Gd.L
3 and 8
] structure minimally, minimising changes to complex 
charge and hydrophilicity. Accordingly, a final set of probe molecules [Gd.L
5 and 10
] was 
prepared, each being derived from 12 (N4, C8) membered macrocyclic ring, tert-butyl ester of 
trans-N
1
,N
7
-DO2A [(7-carbonylmethyl-1,4,7,10-tetraazacyclododec-1-yl)-acetic acid].  
The probe structure retained the same linkage to the antagonists (A and B) and D-biotin was 
appended to the side chain lysine amine, linked to the trans-related ring nitrogen N
10
 of the 
macrocycle (Figure 1). This design was based on the hypothesis that if the cell-surface 
mGluR5 binding is mainly responsible for the increase in R1,cell for [Gd.L
3 and 8
], the 
antagonistic moiety of the newly designed [Gd.L
5 and 10
] would interact with the cell specific 
receptors and the remote, trans-substituted biotin moiety would be available to bind to the 
emissive AvidinAlexaFluor488 (Invitrogen) to allow visualisation of probe localisation by  
optical microscopy techniques. 
Secondary astrocytes expressing mGluR5 were incubated with [Gd.L
5 and 10
] (100 µM, 10-
45 min), and washed with HBSS to remove the unbound probes. Following subsequent 
incubation with AvidinAlexaFluor®488 (25 µM, 5 min, 37°C, 5% CO2), cells were washed 
with HBSS again to eliminate any unbound dye. These AvidinAlexaFluor®488-[Gd.L
5 or 10
]-
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mGluR5 tagged cells were imaged by both TIRF and LSCM. The TIRF images revealed a 
strong signal near the plasma membrane, consistent with receptor tagging; the punctate 
distribution resembled the pattern of the mGluR5 distribution on the cell surface (Figure S1, 
S5
†
). The intracellular sections of these labeled astrocytes were imaged by LCSM, confirming 
the membrane binding of the probes. The intracellular regions of the cells were not 
significantly stained, even following a 45 min. incubation (Figure S5
†
). Further 
demonstration/visualisation of the selective cell-surface labeling of [Gd.L
5 and 10
] was 
provided by examining an HCC projection (Colour coded topological depth map 
reconstruction from the recorded z-stacks (voxel size 120 x 120 x 780 nm) of the optical 
sections reconstructed topological surface map projection of the chosen 7 µm deep section of 
the scanned raster). An HCC projection allows the colour coded depth profile information of 
all the sections to be projected onto one plane (Figure S6
†
, ESI: video S1
†
 and S2
†
). These 
studies also revealed that [Gd.L
10
] labelled better at low concentrations (10 µM [Gd.L
10
], 2.5 
µM of AvidinAlexaFluor®488) compared to [Gd.L
 5
] (Figure S7
†
). 
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Figure 2. Detailed visualisation of the cell surface using TIRF microscopy: (left column) 
and LSCM (right) of live mGluR5 expressing secondary astrocytes after labelling with 
[Gd.L
10
] (10 μM for 10 min), (A) Avidin Alexa-Fluor®488 (green) (2.5 μM for 5 min), (B) 
CellMask
TM 
Orange (red) (5 μg mL-1 for 5 min) and (C) Hoechst 33342 (blue) (1 μg mL-1 for 
5 min). The figure shows the AvidinAlexa-Fluor®488 conjugated to receptors labeled with 
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[Gd.L
10
], CellMask
TM 
Orange staining the cell membrane and Hoechst 33342 labeling cell 
nuclei. Hoechst images in TIRF (Left column, C) were acquired in epifluorescence mode. D: 
depicts an overlay of A, B and C images. Bar size is 11 µm in the TIRF images and 30 µm in 
the LSCM images. 
In order to confirm the cell-surface tagging of mGluR5, a detailed study with [Gd.L 
10
] was 
undertaken. The non-specific plasma membrane stain dye, CellMask
TM 
Orange was used, 
parallel with the nuclear blue stain dye, Hoechst 33342. The secondary astrocytes were 
sequentially incubated with [Gd.L
10
] (10 µM, 10 min), AvidinAlexaFluor®488 dye (2.5 µM, 
5 min), CellMask
TM 
Orange (5 μg mL-1 for 5 min) and Hoechst 33342 (1 μg mL-1 for 5 min). 
During successive incubation, the cells were washed twice with HBSS to remove unreactive 
compounds. The TIRF images displayed a uniform labelling of the plasma membrane by 
CellMask
TM
Orange (Figure 2B), while the [Gd.L
10
]-AvidinAlexaFluor®488 conjugate 
exhibited a punctate cell surface localisation (Figure 2A left). The images obtained by LSCM 
confirmed the results from the TIRF analysis, proving that the conjugate is predominantly 
located on the outside of the cell surface; significant intracellular staining was not observed 
by LCSM; only a few punctate perinuclear fluorescent conjugates (Figure 2A right). The 
Hoechst 33342 images were acquired in epifluorescence mode on the TIRF microscope to 
locate the nuclei in the astrocytes (Figure 2C left). An overlay of the LSCM image depicts the 
orange/green envelope of the plasma membrane, with the blue nuclei shown in the centre 
(Figure 2D right).   
Control experiments 
The specificity of the compounds towards mGluR5 was also investigated by using mGluR5-
negative NIH-3T3 fibroblast cells. As described for the secondary astrocytes, sequential 
loading (equivalent amount and incubation time) of [Gd.L
10
] and AvidinAlexaFluor®488 dye 
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were incubated with NIH-3T3 cells. No staining (cell surface or intracellular localisation) was 
observed strengthening the argument that receptor-mediated binding occurs only on the 
mGluR5 (data not shown). In a further control experiment, the labeling of 
AvidinAlexaFluor®488 on astrocytes did not show any localisation using either microscopy 
technique (data not shown), emphasising that this dye itself cannot be taken up by astrocytes. 
A pre-conjugated construct ([[Gd.L
5 and 10
]-AvidinAlexaFluor®488) also bound with mGluR5 
and no significant uptake in cells were observed (data not shown).  
Cellular receptor-MR imaging probes studies in cell suspensions: Cellular 
1
H-MR 
relaxation enhancement. 
The structural modification of the mGluR5 parent MRI probes [Gd.L
3 and 8
]
(9, 10)
 can have a 
profound effect on their receptor binding efficiency. Therefore, it was necessary to investigate 
the receptor binding behaviour of these newly modified imaging probes [Gd.L
4,5,9,10
] by MRI, 
comparing it with the performance of the parent complexes [Gd.L
3 and 8
]. Primary astrocytes 
were incubated with [Gd.L
3-5 and 8-10
] (100 - 200 µM probe concentrations, 45 min incubation 
time at 37°C, 5% CO2), washed with buffer to remove unbound molecules, re-suspended in 
fresh buffer and subsequently T1-weighted images were recorded on a 3T Siemens human 
whole body MR scanner (Figure 3A). The T1-weighted images were used to calculate cellular 
longitudinal relaxation rates R1,cell, which represents cellular labeling (Figure 3B).
(9, 10)
 The 
complexes [Gd.L
3
] and [Gd.L
8
] showed statistically significant increases in R1,cell, as 
indicated recently (Figure 3B)
(10)
. Furthermore, the trans-substituted biotin probes [Gd.L
5
] 
and [Gd.L
10
] showed similar behaviour (200 µM; increase in R1,cell = 38% and 36%, 
respectively) to the parent analogues ([Gd.L
3 and 8
]). The modulation in R1,cell (R1=1/T1) on 
interacting with mGluR5 were attributed to slower molecular tumbling of the complex 
[increase in rotational correlation time (R)] and fast water exchange rate with bulk water (kex) 
when bound to the cell surface receptors. 
(10)
 
 
 17 
The azaxanthone-based gadolinium probes, [Gd.L
4
 
and 9
] behaved quite differently. No 
significant changes in R1,cell were observed with [Gd.L
4
], whereas the higher concentration 
(200 µM) of [Gd.L
9
] led to a small increase in R1,cell after 45 min of incubation, albeit to a 
lesser extent than its corresponding parent probe [Gd.L
8
] (200 µM [Gd.L
9
]: 113.5% of 
control vs. 200 µM [Gd.L
8
] with 128.2% of control). A significant loss in the apparent R1,cell 
of [Gd.L
4
 
and 9
] can be explained by reference to the luminescence studies of the 
corresponding Tb complexes [Tb.L
4
 
and 9
]. The lanthanide luminescence microscopy studies 
had shown the well-defined punctate vesicular distribution profile, possibly associated with 
lysosomal localization, as seen previously with Ln(III) complexes of related structure and 
overall complex charge.
(28)
 Therefore, it is reasonable to speculate that confinement within 
vesicles restricts the exchange of water molecules that can access the paramagnetic metal 
centre. Such a “relaxation quenching” effect has already been reported by Aime et al(29, 30) 
and has been interpreted in terms of a three compartment relaxation model.
(31)
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Figure 3. (A) T1-weighted MR-images of 1x10
7
 untreated cells (Control) and cells treated for 
45 min with 200 µM of [Gd.DOTA] or [Gd.L
3-5,8-10
]. Images were recorded using a turbo 
spin echo sequence with a matrix of 256 x 256 voxels over a field of view of 110 x 110 mm
2
, 
slice thickness of 1 mm resulting in a voxel size of 0.4 x 0.4 x 1.0 mm
3
), TR 1000 ms, TE 13 
ms, Ti 23 ms and 20 averages. (B) Cellular relaxation rates R1,cell of primary astrocytes after 
treating with increasing concentrations of [Gd.DOTA] or [Gd.L
3-5, 8-10
] for 45 min. Control 
represents cells incubated with HBSS without CA. [Gd.DOTA] served as a negative control. 
Data are means of n=1-6 ± SEM. *P<0.05, **P<0.01, ***P<0.001 vs. control. ANOVA with 
Bonferroni‘s multiple comparison post-test. Note: The concentrations for [Gd.L10] were 142 
µM and 200 µM. 
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Summary and Conclusions 
In conclusion, we have developed probes that specifically target mGluR5 on astrocytes and 
have described the direct observation of cell surface receptor binding using optical imaging 
techniques. By employing a two-step approach, based on a remotely linked biotin-avidin 
interaction, the binding ability of the parent molecule was minimally perturbed and 
characterisation by both MRI and optical methods was rendered possible.  
The next step will focus on the use of longitudinal studies for testing these imaging probes 
using intra-cranial injection directly in the mouse brain to map the mGlu5 receptor density. 
The blood brain barrier (BBB) is the most crucial bottleneck in attaining molecular delivery 
through the blood capillaries. For further clinical application there is an obvious need for non-
invasive delivery of diagnostic agents to the brain. An inability to enter the brain through the 
blood flow, either developing artificial methods for overcoming this barrier are required for 
such anionic complexes delivery in the brain or the successful RCAs could be conjugated 
with already established BBB permeating agents 
[ref]
. We will also extend these encouraging 
results by non-invasively mapping of mGluR5 by MRI in depressed, anxiety and drug-abuse 
mouse models. The potential development of medications for the treatment of addiction and 
other neuropsychiatric disorders, these imaging probes could also provide new pathological 
information of the brain.  
Overall, these synthetic imaging probes could have importance not only in studying cell 
receptor distribution, but also in allowing the study of signalling and activation processes in 
the brain, by allocating specific regions of the brain to be monitored by MRI, following 
functional stimulation. 
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Experimental Methods 
Synthesis of imaging probes. 
(S)-Di-tert-butyl 2,2'-(4-(1-tert-butoxy-5-(2-(3-((2-methylthiazol-4-
yl)ethynyl)phenoxy)ethylamino)-1,5-dioxopentan-2-yl)-10-(2-oxo-2-((5-oxo-5H-
chromeno[2,3-b]pyridin-2-yl)methylamino)ethyl)-1,4,7,10-tetraazacyclododecane-1,7-
diyl)diacetate (11). A solution of 10 (0.2 g, 2.18 mmol), 2-[3-{(2-Methylthiazol-4-
yl)ethynyl}phenoxy]ethanamine (A) (57 mg, 2.18 mmol), NMM (0.06 mL, 4.32 mmol) and 
HOBt (32 mg, 2.4 mmol) in anhydrous DMF (2 mL) was stirred at 0-5
o
C for 15 min and then 
N’-(3-dimethylaminopropyl)-N-ethyl-carbodiimide [EDC] (47 mg, 2.40 mmol) was added. 
The reaction mixtures were stirred for 12 h at room temperature. The completion of reaction 
was verified by TLC. The solution was poured into water (20 mL) and extracted with EtOAc 
(3x20 mL). The combined organic layers were dried over anhydrous Na2SO4, filtered and the 
filtrate evaporated under reduced pressure. The residue was purified by column 
chromatography (silica gel, 10% MeOH in CH2Cl2, Rf= 0.15) to give 11 as a light yellow 
gum (53 mg, 22%). 
1
H NMR (700 MHz, CDCl3):  1.42 (s, 9H, 3xCH3), 1.44 (s, 9H, 3xCH3), 
1.47 (s, 9H, 3xCH3), 2.01 – 2.20 (m, 2H, CH-CH2), 2.23 – 2.40 (m , 2H, CH2-CO-NH), 2.76 
(s, 3H, CH3), 2.79 – 3.60 (br. m, 22H, CO-CH, NH-CH2, CO-CH2, ring CH2), 3.62 – 3.75 (m, 
3H, CO-CH, NH-CH2), 4.08 (t, J=8.00 Hz, 2H, O-CH2), 4.70 (d, J=7.5 Hz, 2H, CH2), 6.13 
(br. s, 1H, NH), 6.87 (d, J=8.5 Hz, 1H, HAr), 7.05 (s, 1H, HAr), 7.17 (d, J=8.0 Hz, 1H, HAr), 
7.19 (d, J=8.0 Hz, 1H, HPy), 7.25 (t, J=8.0 Hz, 1H, HAr), 7.43 (d, J=7.5 Hz, 1H, HAr), 7.59 (t, 
J=8.0 Hz, 1H, HAr), 7.75 (s, 1H, SCHC), 7.78 (d, J=7.5 Hz, 1H, HAr), 8.31 (t, J=8.0 Hz, 1H, 
HAr), 8.64 (d, J=7.5 Hz, 1H, HPy), 9.73 (br. s, 1H, NH). ESI HRMS (±): calcd C58H76N8O11S: 
m/z 1093.5433 [M+H]
+
; found 1093.5453 [M+H]
+
. 
(S)-Di-tert-butyl 2,2'-(4-(1-tert-butoxy-5-(2-(3-(6-(6-methylpyridin-2-
ylcarbamoyl)pyridin-3-yl)phenoxy)ethylamino)-1,5-dioxopentan-2-yl)-10-(2-oxo-2-((5-
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oxo-5H-chromeno[2,3-b]pyridin-2-yl)methylamino)ethyl)-1,4,7,10-
tetraazacyclododecane-1,7-diyl)diacetate (12). A solution of 10 (0.17 g, 1.86 mmol), amine 
(B) (65 mg, 1.86 mmol), NMM (0.05 mL, 3.71 mmol) and HOBt (28 mg, 2.04 mmol) in 
anhydrous DMF (2 mL) was stirred at 0-5
o
C for 15 min and then N’-(3-
dimethylaminopropyl)-N-ethyl-carbodiimide [EDC] (40 mg, 2.04 mmol) was added. The 
reaction mixtures were stirred for 12 h at room temperature. The completion of reaction was 
verified by TLC. The solution was poured into water (20 mL) and extracted with EtOAc 
(3x20 mL). The combined organic layers were dried over anhydrous Na2SO4, filtered and the 
filtrate evaporated under reduced pressure. The residue was purified by column 
chromatography (silica gel, 10% MeOH in CH2Cl2, Rf= 0.15) to give 12 as a light yellow 
gum (61 mg, 22%). 
1
H NMR (400 MHz, CDCl3):  1.37 (s, 9H, 3xCH3), 1.44 (s, 9H, 3xCH3), 
1.46 (s, 9H, 3xCH3), 1.92 – 2.03 (m, 2H, CH-CH2), 2.18 – 2.36 (m, 2H, CH2-CO-NH), 3.56 
(s, 3H, CH3), 2.64 – 3.88 (br. m, 22H, CO-CH, NH-CH2, CO-CH2, ring CH2, CO-CH, NH-
CH2), 4.06 (t, J=8.00 Hz, 2H, O-CH2), 4.69 (d, J=7.5 Hz, 2H, CH2), 6.89 (d, J=8.5 Hz, 1H, 
HPy), 6.97 (d, J=7.5 Hz, 2H, HAr), 7.30 - 7.40 (m, 5H, 5xHAr, HPy), 7.44 (s, 1H, NH), 7.46 (s, 
1H, NH),  7.68 (t, J=8.0 Hz, 1H, HPy), 7.70 (t, J=8.0 Hz, 1H, HPy),  7.77 (d, J=7.0 Hz, 1H, 
HPy), 7.95 (d, J=8.0 Hz, 1H, HPy), 8.26 (d, J=8.5 Hz, 1H, HPy), 8.26 (d, J=8.5 Hz, 1H, HAr), 
8.55 (d, J=8.5 Hz, 1H, HPy), 8.72 (s, 1H, HPy), 10.61 (br. s., 1H, NH). ESI HRMS (±): calcd 
C58H76N8O11S: m/z 1183.6186 [M+H]
+
; found 1183.6221 [M+H]
+
. 
Common synthesis of L
4
 and L
9
. Compounds 11/12 (1 equiv.) were dissolved in 
TFA:CH2Cl2 (9:1 mL) and stirred overnight. The solvent was removed by evaporation and 
dried under reduced pressure. 
(S)-2,2'-(4-(1-Carboxy-4-(2-(3-((2-methylthiazol-4-yl)ethynyl)phenoxy)ethylamino)-4-
oxobutyl)-10-(2-oxo-2-((5-oxo-5H-chromeno[2,3-b]pyridin-2-yl)methylamino)ethyl)-
1,4,7,10-tetraazacyclododecane-1,7-diyl)diacetic acid (L
4
): L
4 
was obtained as an off-white 
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sticky solid (13.5 mg, 32%). 
1
H NMR (400 MHz, D2O):  1.76 – 2.04 (m, 2H, CH-CH2), 2.95 
– 3.13 (m , 2H, CH2-CO-NH), 3.21 (s, 3H, CH3), 2.75 – 3.82 (br. m, 25H, CO-CH, NH-CH2, 
CO-CH2, CH2 ring), 3.85 - 4.24 (m, 4H, CH2-CO, NH-CH2), 6.88 (d, J=8.0 Hz, 1H, HAr), 7.02 
(s, 1H, HAr), 7.20 (t, J=8.0 Hz, 1H, HAr), 7.35 – 7.69 (m, 4H, HAr, HPy), 7.81 (s, 1H, S-CH-C), 
8.16 (t, J=7.5 Hz 1H, HAr), 8.57 (d, J=8.0 Hz, 1H, HAr), 8.78 (d, J=7.5 Hz, 1H, HPy). ESI 
LRMS (±): calcd C46H52N8O11S: m/z 925.3 [M+H]
+
; found 925.7 [M+H]
+
. 
(S)-2,2'-(4-(1-Carboxy-4-(2-(3-(6-(6-methylpyridin-2-ylcarbamoyl)pyridin-3-
yl)phenoxy)ethylamino)-4-oxobutyl)-10-(2-oxo-2-((5-oxo-5H-chromeno[2,3-b]pyridin-2-
yl)methylamino)ethyl)-1,4,7,10-tetraazacyclododecane-1,7-diyl)diacetic acid (L
9
): L
9 
was 
obtained as an off-white sticky solid (15 mg, 29%). 
1
H NMR (400 MHz, MeOD):  2.02 – 
2.58 (m, 4H, CHCH2CH2CONH), 2.68 (s, 3H, CH3), 2.72 – 4.02 (br. m, 27H, NH-CH2, CO-
CH, O-CH2, CO-CH2, ring CH2), 4.37 (d, J=7.5 Hz, 2H, CH2), 6.89 (d, J=8.5 Hz, 1H, HPy), 
7.13 (d, J=7.5 Hz, 1H, HPy), 7.31 (d, J=7.5 Hz, 1H, HPy), 7.35 (d, J=8.5 Hz, 1H, HAr), 7.38 (t, 
J=8.0 Hz, 1H, HAr),  7.48 (t, J=8.0 Hz, 1H, HPy), 7.57 (d, J=8.5 Hz, 2H, HAr), 7.71 (d, J=7.0 
Hz, 2H, HAr), 7.92 (t, J=7.5 Hz, 1H, HAr), 8.03 (d, J=8.0 Hz, 1H, HPy),  8.06 (d, J=8.0 Hz, 1H, 
HAr), 8.10 (d, J=8.0 Hz, 1H, HPy),  8.48 (d, J=8.5 Hz, 1H, HPy), 8.75 (s, 1H, HPy). ESI LRMS 
(+): calcd C52H58N10O12S: m/z 1015.2 [M+H]
+
; found 1015.5 [M+H]
+
. 
Common synthesis of [Ln.L
4
] and [Ln.L
9
]. Gadolinium complexes [Ln.L
4
] and [Ln.L
9
] 
were prepared from corresponding solutions of the ligands L
4
/ L
9
 (1 eq) and solutions of 
LnCl3.6H2O (Ln
3+ 
= Gd
3+
, Tb
3+
; 1.1 eq). The reaction mixture was stirred at 60° C for 20 h. 
The pH was periodically checked and adjusted to 6.0 using solutions of NaOH (1 M) and HCl 
(1 N) as needed. After completion, the reaction mixture was cooled down and passed through 
Chelex-100 to trap free Ln
3+
 ions, and the Ln
3+
-loaded complexes were eluted. The fractions 
were dialyzed (500 M.Wt cutoff; Spectra/Pro® biotech cellulose ester dialysis membrane, 
Spectrum Laboratories) and lyophilized to obtain off-white solids. The absence of free Ln
3+
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was checked with xylenol orange indicator. These complexes were characterized by ESI-
LRMS in positive /negative modes and the appropriate isotope pattern distribution for Ln
3+
 
were recorded. 
[Tb.L
4
]. ESI LRMS (-): calcd C46H49N8O11STb: m/z 1079.24 [M-H]
-
; found 1079.27 [M-H]
-
. 
[Gd.L
4
]. ESI LRMS (-): calcd C46H49GdN8O11S: m/z 1078.24 [M-H]
-
; found 1078.60 [M-H]
-
. 
r1p = 7.49 mM
-1
s
-1
 (60 MHz, 310K). 
[Tb.L
9
]. ESI LRMS (-): calcd C52H55N10O12Tb: m/z 1169.32 [M-H]
-
; found 1169.69 [M-H]
-
. 
[Gd.L
9
]. ESI LRMS (-): calcd C52H55GdN10O12: m/z 1168.32 [M-H]
-
; found 1168.74 [M-H]
-
. 
r1p = 7.98 mM
-1
s
-1
 (60 MHz, 310K). 
Di-tert-butyl 2,2'-(4-((R)-6-(benzyloxycarbonylamino)-1-tert-butoxy-1-oxohexan-2-yl)-10-
((S)-1-tert-butoxy-5-(2-(3-((2-methylthiazol-4-yl)ethynyl)phenoxy)ethylamino)-1,5-
dioxopentan-2-yl)-1,4,7,10-tetraazacyclododecane-1,7-diyl)diacetate (15). A solution of 14 
(90 mg,  0.96 mmol), 2-[3-{(2-Methylthiazol-4-yl)ethynyl}phenoxy]ethanamine (A) (25 mg, 
0.96 mmol), NMM (0.028 mL, 1.98 mmol) and HOBt (15 mg, 1.11 mmol) in anhydrous DMF 
(1 mL) was stirred at 0-5
o
C for 15 min and then EDC (22 mg, 1.11 mmol) was added. The 
reaction mixtures were stirred for 18 h at room temperature. The completion of reaction was 
verified by TLC. The solution was poured into water (20 mL) and extracted with EtOAc 
(3x20 mL). The combined organic layers were dried over anhydrous Na2SO4, filtered and the 
filtrate evaporated under reduced pressure. The residue was purified by column 
chromatography (silica gel, 10% MeOH in CH2Cl2, Rf= 0.35) to give 11 as a light yellow 
gum (22 mg, 20%). 
1
H NMR (400 MHz, CDCl3):  1.19 – 1.36 (m, 4H, CH2), 1.38 (s, 9H, 
3xCH3), 1.41 (s, 9H, 3xCH3), 1.43 (s, 9H, 3xCH3), 1.44 (s, 9H, 3xCH3), 1.84 – 2.62 (m, 6H, 
CH2), 2.72 (s, 3H, CH3), 2.73 – 3.55 (br. m, 23H, CO-CH, NH-CH2, CO-CH2, ring CH2), 3.58 
– 3.77 (m, 3H, CO-CH, NH-CH2), 4.02 (t, J=8.00 Hz, 2H, O-CH2), 5.06 (s, 2H, CH2), 6.19 
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(br. s, 1H, NH), 6.34 (br. s., 1H, NH), 6.88 (d, J=9.0 Hz, 1H, HAr), 7.04 (s, 1H, HAr), 7.14 (t, 
J=8.5 Hz, 1H, HAr), 7.24 (d, J=9.0 Hz, 1H, HAr), 7.27 - 7.35 (m, 5H, HAr), 7.37 (s, 1H, C-CH-
S). 13C NMR (101 MHz, CDCl3):  19.1, 23.1, 26.4, 27.6, 27.7, 28.2, 29.2, 32.5, 32.6, 38.8, 
43.6, 53.3, 54.9, 55.6, 55.9, 58.1, 66.3, 66.6, 68.8, 69.9, 81.8, 82.0, 82.3, 83.3, 88.4, 115.5, 
117.0, 122.4, 123.5, 124.6, 128.4, 129.5, 134.9, 136.6, 144.1, 156.5, 158.1, 165.7, 170.5, 
172.8, 173.4, 174.8.  ESI HRMS (±): calcd C61H91N7O13S: m/z 1146.6519 [M+H]
+
; found 
1146.6498 [M+H]
+
. 
Di-tert-butyl 2,2'-(4-((R)-6-(benzyloxycarbonylamino)-1-tert-butoxy-1-oxohexan-2-yl)-10-
((S)-1-tert-butoxy-5-(2-(3-(6-(6-methylpyridin-2-ylcarbamoyl)pyridin-3-
yl)phenoxy)ethylamino)-1,5-dioxopentan-2-yl)-1,4,7,10-tetraazacyclododecane-1,7-
diyl)diacetate (16). A solution of 14 (90 mg, 0.96 mmol), 5-[4-(2-Aminoethoxy)phenyl]-N-
(6-methylpyridin-2-yl)picolinamide (B) (35 mg, 0.96 mmol), NMM (0.028 mL, 1.98 mmol) 
and HOBt (15 mg, 1.11 mmol) in anhydrous DMF (1 mL) was stirred at 0-5
o
C for 15 min and 
then EDC (22 mg, 1.11 mmol) was added. The reaction mixtures were stirred for 18 h at room 
temperature. The completion of reaction was verified by TLC. The solution was poured into 
water (20 mL) and extracted with EtOAc (3x20 mL). The combined organic layers were dried 
over anhydrous Na2SO4, filtered and the filtrate evaporated under reduced pressure. The 
residue was purified by column chromatography (silica gel, 10% MeOH in CH2Cl2, Rf= 0.4) 
to give 11 as a light yellow gum (31 mg, 25%). 
1
H NMR (700 MHz, CDCl3):  1.19 – 1.39 
(m, 4H, CH2), 1.44 (s, 9H, 3xCH3), 1.45 (s, 9H, 3xCH3), 1.47 (s, 9H, 3xCH3), 1.48 (s, 9H, 
3xCH3), 1.95 – 2.11 (m, 2H, CH2), 2.13 – 2.27 (m , 2H, CH2), 2.33 (t , J=8.00 Hz ,2H, CH2), 
2.53 (s, 3H, CH3), 2.71 – 3.52 (br. m, 23H, CO-CH, NH-CH2, CO-CH2, ring CH2), 3.58 – 
3.77 (m, 3H, CO-CH, NH-CH2), 4.12 (t, J=8.00 Hz, 2H, CH2), 4.84 (br. s., 1H, NH), 5.09 (s, 
2H, CH2), 6.55 (br. s., 1H, NH), 6.94 (d, J=7.5 Hz, 1H, HPy), 7.08 (d, J=8.50 Hz, 2H, HAr), 
7.28 - 7.37 (m, 5H, HAr), 7.57 (d, J=8.50 Hz, 2H, HAr), 7.66 (t, J=8.00 Hz, 1H, HPy), 8.03 (d, 
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J=8.00 Hz, 1H, HPy), 8.25 (d, J=8.00 Hz, 1H, HPy), 8.30 (d, J=8.00 Hz, 1H, HPy), 8.80 (s, 1H, 
HPy), 10.49 (br. s., 1H, NH). 
13
C NMR (176 MHz, CDCl3):   24.1, 24.3, 26.4, 27.8, 28.0, 
28.1, 29.2, 31.7, 34.9, 36.4, 38.5, 52.6, 53.4, 55.9, 60.4, 61.1, 66.4, 66.5, 68.3, 69.4, 81.8, 
81.9, 82.0, 82.3, 110.7, 115.5, 119.2, 122.4, 128.1, 128.3, 128.5, 134.9, 135.5, 136.5, 138.5, 
139.2, 146.1, 147.2, 150.5, 156.3, 157.0, 159.5, 162.6, 172.8, 172.8, 173.1, 174.7, 175.1. ESI 
HRMS (±): calcd C67H97N9O13: m/z 1236.7278 [M+H]
+
; found 1236.7267 [M+H]
+
. 
2,2'-(4-((R)-5-Amino-1-carboxypentyl)-10-((S)-1-carboxy-4-(2-(3-((2-methylthiazol-4-
yl)ethynyl)phenoxy)ethylamino)-4-oxobutyl)-1,4,7,10-tetraazacyclododecane-1,7-
diyl)diacetic acid (17). A solution of 15 (20 mg, 0.18 mmol) in H2O (1 mL), 0.15 M Ba(OH)2 
(0.06 mL, 0.54 mmol) and glyme (5 mL) was stirred at 60 

C for overnight. The reaction 
mixture was evaporated under reduced pressure. The crude intermediate product was 
dissolved in TFA:CH2Cl2 (9:1 mL) and stirred overnight. The solvent was removed by 
evaporation and dried under reduced pressure to give 17 as a yellow gum (10.9 mg, 78%). 
1
H 
NMR (700 MHz, MeOD):  1.48 – 1.64 (m, 2H, CH2), 1.68 – 2.01 (m, 4H, CH2), 2.04 – 2.19 
(m, 2H, CH2CO-NH), 2.71 (s, 3H, CH3), 2.90 – 3.40 (br. m, 22H, ring CH2, CO-CH, CH2-
NH2, CH-CH2), 3.47 – 3.53 (m, 2H, CO-NH-CH2), 3.54 – 3.61 (m, 4H, CH2-CO), 4.05 (t, 
J=8.00 Hz, 2H, O-CH2), 6.96 -7.04 (m, 1H, HAr), 7.06 – 7.17 (m, 2H, HAr), 7.29 (t, J=8.0 Hz, 
1H, HAr), 7.64 (s, 1H, C-CH-S). ESI LRMS (+): calcd C37H53N7O10S: m/z 788.3 [M+H]
+
; 
found 788.5 [M+H]
+
. 
2,2'-(4-((R)-5-Amino-1-carboxypentyl)-10-((S)-1-carboxy-4-(2-(3-(6-(6-methylpyridin-2-
ylcarbamoyl)pyridin-3-yl)phenoxy)ethylamino)-4-oxobutyl)-1,4,7,10-
tetraazacyclododecane-1,7-diyl)diacetic acid (18). A solution of 16 (30 mg, 0.24 mmol), 
(10%) Pd-C (1/5, w/w) in MeOH (5 mL) under H2 (40 psi) was stirred at room temperature in 
a Parr apparatus for 4 h. The reaction mixture was filtered through Celite, the filtrate 
evaporated under reduced pressure. The crude intermediate product was dissolved in 
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TFA:CH2Cl2 (9:1 mL) and stirred overnight. The solvent was removed by evaporation and 
dried under reduced pressure to give 18 as a yellow gum (14.3 mg, 65%). 
1
H NMR (700 
MHz, MeOD):  1.40 – 1.55 (m, 2H, CH2), 1.60 – 1.73 (m, 2H, CH2), 1.77 – 1.90 (m, 2H, 
CH2), 1.93 – 2.08 (m , 2H, CH2), 2.19 - 2.38 (m ,2H, CH2), 2.44 (s, 3H, CH3), 2.70 – 3.47 (br. 
m, 24H, CO-CH, NH-CH2, CO-CH2, ring CH2), 3.48 – 3.67 (m, 2H, NH-CH2), 4.02 (t, J=8.00 
Hz, 2H, O-CH2), 6.84 (d, J=8.0 Hz, 1H, HPy), 7.03 (d, J=8.0 Hz, 2H, HAr), 7.63 (d, J=8.0 Hz, 
2H, HAr), 7.76 (t, J=7.5 Hz, 1H, HPy), 8.10 (d, J=8.00 Hz, 1H, HPy), 8.13 (d, J=8.00 Hz, 1H, 
HPy), 8.14 (d, J=8.00 Hz, 1H, HPy), 8.87 (s, 1H, HPy). ESI LRMS (+): calcd C43H59N9O11: m/z 
878.4 [M+H]
+
; found 878.5 [M+H]
+
. 
Common synthesis of gadolinium complexes [Gd.17] and [Gd.18]. Gadolinium complexes 
[Gd.17] and [Gd.18] were prepared from corresponding solutions of the ligands 17/18 (1 eq) 
and solutions of GdCl3.6H2O (1.1 eq). The reaction mixture was stirred at 60° C for 20 h. The 
pH was periodically checked and adjusted to 6.0 using solutions of NaOH (1 M) and HCl (1 
N) as needed. After completion, the reaction mixture was cooled down and passed through 
Chelex-100 to trap free Gd
3+
 ions, and the Gd
3+
-loaded complexes were eluted. The fractions 
were dialyzed (500 M.Wt cutoff; Spectra/Pro® biotech cellulose ester dialysis membrane, 
Spectrum Laboratories) and lyophilized to obtain off-white solids. The absence of free Gd
3+
 
was checked with xylenol orange indicator. These complexes were characterized by ESI-
LRMS in positive /negative modes and the appropriate isotope pattern distribution for Gd
3+
 
were observed.  
[Gd.17]. Yield = 12 mg, 100% (an off white solid). ESI LRMS (+): calcd C37H49GdN7O10S: 
m/z 942.25 [M+H]
+ 
and 471.32[M+2H]
2+
; found 942.79 [M+H]
+
 and 471.98 [M+2H]
2+
 . 
[Gd.18]. Yield = 17 mg, 100% (an off white solid). ESI LRMS (+): calcd C43H55GdN9O11: 
m/z 516.33 [M+2H]
2+
; found 516.55 [M+2H]
2+
 .  
 
 28 
Common synthesis of [Gd.L
5
] and [Gd.L
10
]. A solution of [Gd.17]/ [Gd.18] (1 equiv.), D-
biotin (1.1 equiv.), DIPEA (2 equiv.) and HATU (1.1 equiv.) in anhydrous DMF (1 mL) was 
stirred overnight at room temperature. The completion of reaction was verified by LRMS. The 
solution was evaporated under reduced pressure, purified by RP-HPLC and lyophilized to 
obtain off-white solids. 
[Gd.L
5
]. Yield = 3.26 mg, 22%. ESI-LRMS (±): calcd C47H63GdN9O12S2: m/z 1166.32 [M-
H]
- 
and 584.32[M+2H]
2+
; found 1166.80 [M-H]
-
 and 584.07 [M+2H]
2+
, tR = 12.6 min, r1p = 
7.23 mM
-1
s
-1
 (60 MHz, 310K). 
[Gd.L
10
]. Yield = 3.1 mg, 15%. ESI-LRMS (±): C53H69GdN11O13S: m/z 1256.40 [M-H]
- 
and 
629.40 [M+2H]
2+
; found 1256.90 [M-H]
-
 and 629.17 [M+2H]
2+
, tR = 12.9, r1p = 7.88 mM
-1
s
-1
 
(60 MHz, 310K). 
Total Internal Reflection Fluorescence (TIRF) Microscopy. TIRF microscopy was 
performed on an inverted Leica TIRF MC Imaging system with excitation lasers set to 405, 
488 and 561 nm to visualize Hoechst, GFP and Cell mask. Acquisition was performed using 
an 100×/HCX Plan Apo Oil TIRF 1.47 objective. Imaging and image capture was performed 
using LASAF software. 
Confocal Microscopy. Cell images and co-localization experiments were obtained using a 
Leica SP5 II microscope. A HeNe laser was used to visualize SA-AF488
 
fluorescence. The 
microscope was equipped with a triple channel imaging detector, comprising two 
conventional PMT systems and a HyD hybrid avalanche photodiode detector. The latter part 
of the detection system, when operated in the BrightRed mode, is capable of improving 
imaging sensitivity above 550 nm by 25%, reducing signal to noise by a factor of 5. The 
pinhole was always determined by the Airy disc size, calculated from the objective in use 
(HCX PL APO 63x/1.40 NA LbdBlue), using the lowest excitation wavelength (488 nm). 
Scanning speed was adjusted to 400 Hz in a bidirectional mode, to ensure both sufficient light 
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exposure and enough time to collect the emitted light from the optical probes (1024 x 1024 
frame size, a pixel size of 120 x 120 nm and depth of 0.89 μm). The 3D reconstruction was 
achieved using a novel saturation elimination algorithm update of the existing ImageJ 1.46r 
3D plug-in using, LSCM images recorded on the above detailed Leica SP5 II microscope. In 
these z-stack images, a deliberate 20% overlap in the applied axial resolution was introduced, 
determined by the applied optics and experimental parameters detailed above. 
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